Small molecule · Inhibitor of phosphoinositide-3-kinase gamma (PIK3CG) · developed by Arcus Biosciences
Eganelisib (IPI-549) is an orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma). It acts by blocking PI3K-gamma-mediated signaling in tumor cells and immune cells that express the isoform, and is studied in triple-negative breast cancer and ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03719326 | Phase 1 | TNBC - Triple-Negative Breast Cancer | Completed | RCUS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ovarian CancerTNBC - Triple-Negative Breast Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the RCUS page.
See RCUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RCUS catalysts and pipeline →